NCT01430572 - Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2011

Primary Completion Date

May 12, 2020

Study Completion Date

May 12, 2020

Conditions

Advanced CancersSolid Tumors

Interventions

DRUG

Pazopanib

Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.

DRUG

Everolimus

"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston